Myriad Genetics (MYGN) Shares Bought by Comerica Bank

Comerica Bank raised its stake in shares of Myriad Genetics (NASDAQ:MYGN) by 1.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 121,244 shares of the company’s stock after buying an additional 2,153 shares during the period. Comerica Bank’s holdings in Myriad Genetics were worth $3,521,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Meadow Creek Investment Management LLC increased its stake in Myriad Genetics by 19.4% during the 4th quarter. Meadow Creek Investment Management LLC now owns 11,322 shares of the company’s stock valued at $389,000 after buying an additional 1,836 shares during the period. Meeder Asset Management Inc. increased its stake in Myriad Genetics by 58.3% during the 4th quarter. Meeder Asset Management Inc. now owns 5,210 shares of the company’s stock valued at $179,000 after buying an additional 1,918 shares during the period. Teachers Advisors LLC increased its stake in Myriad Genetics by 1.7% during the 4th quarter. Teachers Advisors LLC now owns 117,695 shares of the company’s stock valued at $4,042,000 after buying an additional 1,948 shares during the period. KBC Group NV increased its stake in Myriad Genetics by 37.5% during the 4th quarter. KBC Group NV now owns 7,193 shares of the company’s stock valued at $247,000 after buying an additional 1,962 shares during the period. Finally, SG Americas Securities LLC grew its stake in shares of Myriad Genetics by 42.2% in the 4th quarter. SG Americas Securities LLC now owns 6,673 shares of the company’s stock worth $229,000 after purchasing an additional 1,979 shares during the last quarter.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Friday. ValuEngine cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 13th. Morgan Stanley lifted their price objective on shares of Myriad Genetics from $33.00 to $35.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 9th. BidaskClub raised shares of Myriad Genetics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 20th. Finally, Leerink Swann lifted their price objective on shares of Myriad Genetics from $33.00 to $35.00 and gave the stock a “market perform” rating in a research note on Wednesday, February 7th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $31.17.

Shares of Myriad Genetics opened at $35.40 on Friday, according to Marketbeat. Myriad Genetics has a one year low of $19.75 and a one year high of $41.57. The stock has a market capitalization of $2.44 billion, a price-to-earnings ratio of 33.71, a PEG ratio of 3.77 and a beta of 0.51. The company has a quick ratio of 3.16, a current ratio of 3.52 and a debt-to-equity ratio of 0.07.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.04. The firm had revenue of $193.50 million for the quarter, compared to analyst estimates of $188.22 million. Myriad Genetics had a net margin of 17.67% and a return on equity of 9.52%. The company’s revenue for the quarter was down 1.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.27 earnings per share. analysts anticipate that Myriad Genetics will post 1.2 earnings per share for the current fiscal year.

Myriad Genetics Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics (NASDAQ:MYGN).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply